Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Nutr. 2014 Jan 28;111(2):279-86. doi: 10.1017/S0007114513002237. Epub 2013 Oct 8.

Short-term, daily intake of yogurt containing Bifidobacterium animalis ssp. lactis Bf-6 (LMG 24384) does not affect colonic transit time in women.

Author information

1
Department of Family Medicine, Georgetown University Medical Center, 240 Building D, 4000 Reservoir Road NW, Washington, DC 20007-2145, USA.
2
Department of Mathematics, UPMC, St. Margaret Hospital, Duquesne University, Pittsburgh, PA, USA.
3
Division of Gastroenterology, Department of Medicine, Georgetown University Medical Center, Washington, DC, USA.
4
Cargill, Inc., Wayzata, MN, USA.
5
Department of Food Science, The Pennsylvania State University, University Park, PA, USA.

Abstract

The present study investigated the effect of Bifidobacterium animalis ssp. lactis Bf-6 (LMG 24 384) (Bf-6)-supplemented yogurt on colonic transit time (CTT). A triple-blinded, randomised, placebo-controlled, two-period cross-over trial was conducted with sixty-eight women with a self-reported history of straining during bowel movements or hard or lumpy stools in the past 2 years. As per regulatory requirements for probiotic studies, eligible women were generally healthy and not actively constipated at the time of enrolment. Participants consumed both Bf-6 and placebo yogurts for 14 d each in a randomised order, with a 6-week washout period between the treatments. The primary outcome, CTT, was assessed via Sitz marker X-rays. The average CTT was 42·1 h for the active period and 43·3 h for the control period (mean difference 1·2 h, 95 % CI - 4·9, 7·4). Since the statistical tests for the cross-over study implied that the mean CTT for the active and control periods in period 2 were biased, the standard protocol suggests examining the results of only period 1 as a traditional randomised controlled trial. This showed that the mean CTT was 35·2 h for the active period v. 52·9 h for the control period (P= 0·015). Bootstrapping demonstrated that both the mean and median differences remained significant (P= 0·016 and P= 0·045, respectively). Few adverse events were noted, with no differences among the active and control periods. The paired analysis showed no differences between the active and control periods during the cross-over trial. Further trials should be conducted in populations with underlying problems associated with disordered transit to determine the potential value of probiotic supplementation more accurately.

PMID:
24103188
DOI:
10.1017/S0007114513002237
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Cambridge University Press
    Loading ...
    Support Center